<?xml version='1.0' encoding='utf-8'?>
<document id="32249350"><sentence text="Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis."><entity charOffset="121-131" id="DDI-PubMed.32249350.s1.e0" text="flecainide" /></sentence><sentence text="Higher drug concentrations in complex clinical scenarios in which multiple factors such as drug-drug interactions (DDIs) and comorbidities are simultaneously present are not necessarily rationalized in prospective clinical studies" /><sentence text=" Physiologically based pharmacokinetic (PBPK) modeling and simulation of the anti-arrhythmic drug flecainide, as an example, were utilized to quantitatively rationalize the higher flecainide concentration in a complex clinical case involving end-stage renal disease (ESRD), cirrhosis, and the co-administration of mexiletine, a CYP1A2 inhibitor"><entity charOffset="98-108" id="DDI-PubMed.32249350.s3.e0" text="flecainide" /><entity charOffset="180-190" id="DDI-PubMed.32249350.s3.e1" text="flecainide" /><entity charOffset="314-324" id="DDI-PubMed.32249350.s3.e2" text="mexiletine" /><pair ddi="false" e1="DDI-PubMed.32249350.s3.e0" e2="DDI-PubMed.32249350.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32249350.s3.e0" e2="DDI-PubMed.32249350.s3.e1" /><pair ddi="false" e1="DDI-PubMed.32249350.s3.e0" e2="DDI-PubMed.32249350.s3.e2" /><pair ddi="false" e1="DDI-PubMed.32249350.s3.e1" e2="DDI-PubMed.32249350.s3.e1" /><pair ddi="false" e1="DDI-PubMed.32249350.s3.e1" e2="DDI-PubMed.32249350.s3.e2" /></sentence><sentence text="" /><sentence text="The developed flecainide PBPK model was used to evaluate the DDI effect (as measured by AUC ratio before and after inhibition) of mexiletine and the combined disease effects of ESRD and cirrhosis on flecainide exposure"><entity charOffset="14-24" id="DDI-PubMed.32249350.s5.e0" text="flecainide" /><entity charOffset="130-140" id="DDI-PubMed.32249350.s5.e1" text="mexiletine" /><entity charOffset="199-209" id="DDI-PubMed.32249350.s5.e2" text="flecainide" /><pair ddi="false" e1="DDI-PubMed.32249350.s5.e0" e2="DDI-PubMed.32249350.s5.e0" /><pair ddi="false" e1="DDI-PubMed.32249350.s5.e0" e2="DDI-PubMed.32249350.s5.e1" /><pair ddi="false" e1="DDI-PubMed.32249350.s5.e0" e2="DDI-PubMed.32249350.s5.e2" /><pair ddi="false" e1="DDI-PubMed.32249350.s5.e1" e2="DDI-PubMed.32249350.s5.e1" /><pair ddi="false" e1="DDI-PubMed.32249350.s5.e1" e2="DDI-PubMed.32249350.s5.e2" /></sentence><sentence text="" /><sentence text="The predicted DDI effect of mexiletine was negligible or weak in anuric hemodialysis with cirrhosis population (mean [5th/95th percentiles], 1"><entity charOffset="28-38" id="DDI-PubMed.32249350.s7.e0" text="mexiletine" /></sentence><sentence text="23 [0" /><sentence text="97-1" /><sentence text="67]), although it was negligible in healthy volunteers (1" /><sentence text="03 [1" /><sentence text="02-1" /><sentence text="05])" /><sentence text=" The predicted flecainide concentrations after multiple flecainide doses (50 mg BID) in the anuric hemodialysis with cirrhosis population were comparable with the observed value (3602 ng/mL), which fell between the predicted concentrations in the absence and presence of mexiletine (3043 [718-8499] and 5914 [880-20,624] ng/mL, respectively)"><entity charOffset="15-25" id="DDI-PubMed.32249350.s14.e0" text="flecainide" /><entity charOffset="56-66" id="DDI-PubMed.32249350.s14.e1" text="flecainide" /><entity charOffset="271-281" id="DDI-PubMed.32249350.s14.e2" text="mexiletine" /><pair ddi="false" e1="DDI-PubMed.32249350.s14.e0" e2="DDI-PubMed.32249350.s14.e0" /><pair ddi="false" e1="DDI-PubMed.32249350.s14.e0" e2="DDI-PubMed.32249350.s14.e1" /><pair ddi="false" e1="DDI-PubMed.32249350.s14.e0" e2="DDI-PubMed.32249350.s14.e2" /><pair ddi="false" e1="DDI-PubMed.32249350.s14.e1" e2="DDI-PubMed.32249350.s14.e1" /><pair ddi="false" e1="DDI-PubMed.32249350.s14.e1" e2="DDI-PubMed.32249350.s14.e2" /></sentence><sentence text="" /><sentence text="The PBPK simulation proposed a likely explanation that the observed higher flecainide concentration could be attributed to the combined effects of ESRD, cirrhosis, and a potential DDI with mexiletine"><entity charOffset="75-85" id="DDI-PubMed.32249350.s16.e0" text="flecainide" /><entity charOffset="189-199" id="DDI-PubMed.32249350.s16.e1" text="mexiletine" /><pair ddi="false" e1="DDI-PubMed.32249350.s16.e0" e2="DDI-PubMed.32249350.s16.e0" /><pair ddi="false" e1="DDI-PubMed.32249350.s16.e0" e2="DDI-PubMed.32249350.s16.e1" /></sentence><sentence text=" This approach provides quantitative insight into theoretically conceivable extremes in drug exposure occurring in complex clinical situations even if uncommon" /><sentence text="" /></document>